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A B S T R A C T
Objectives: The aim of this study was to assess the influence of renal function, in particular the presence of
augmented renal clearance (ARC), on the pharmacokinetics of linezolid in critically ill patients. The effect
of continuous infusion on the probability of therapeutic success from a pharmacokinetic/pharmacody-
namic (PK/PD) perspective was also evaluated.
Methods: Seventeen patients received linezolid (600 mg every 12 h) as a 30-min infusion and 26 as a
continuous infusion (50 mg/h). The PK parameters were calculated and the probability of PK/PD target
attainment (PTA) was estimated by Monte Carlo simulation (MCS) for different doses administered by
intermittent (600 mg every 12 h or 600 mg every 8 h) or continuous infusion (50 mg/h or 75 mg/h).
Results: In patients without ARC, the standard dose was adequate to attain the PK/PD target. However,
linezolid clearance was significantly higher in ARC patients, leading to sub-therapeutic concentrations.
Continuous infusion (50 mg/h) provided concentrations 2 mg/l in 70% of the ARC patients. MCS revealed
that concentrations 2 mg/l would be reached in >90% of patients receiving 75 mg/h.
Conclusions: ARC increases linezolid clearance and leads to a high risk of underexposure with the
standard dose. Continuous infusion increases the PTA, but an infusion rate of 75 mg/h should be
considered to ensure concentrations 2 mg/ml.
© 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
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Nowadays, antimicrobial treatment remains challenging, espe-
cially in critically ill patients, mainly due to their severe clinical
condition, and also because they often undergo pathophysiological
changes that may alter the pharmacokinetics of drugs (Blot et al.,
2014). Some of the most commonly observed alterations are an
increased volume of distribution (Vd), altered protein binding, and
changes in drug clearance due to hepatic or renal dysfunction.* Corresponding author at: Arantxa Isla Ruiz, Department of Pharmacy and Food
Sciences, Faculty of Pharmacy, Paseo de la Universidad 7, 01006 Vitoria-Gasteiz,
Spain.
E-mail address: arantxa.isla@ehu.eus (A. Isla).
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Para uso personal exclusivamente. No se permiten otros usos sin autorizaTraditionally, renal function in critically ill patients has been
assessed to identify renal dysfunction, and dose adjustment is
generally accepted in this context. Nevertheless, augmented renal
clearance (ARC) is a less well-studied phenomenon that could lead
to faster elimination of drugs, resulting in sub-therapeutic
concentrations and poorer clinical outcomes when standard
dosage guidelines are followed (Bilbao-Meseguer et al., 2018).
ARC refers to the enhanced elimination of solutes as compared
with an expected baseline, and it is defined as creatinine clearance
(CrCL) of 130 ml/min/1.73 m2. This manifestation of enhanced
renal function is seen in 20% to 65% of critically ill patients (Bilbao-
Meseguer et al., 2018; Udy et al., 2014).
Several conditions have been described as risk factors for ARC,
such as younger age, trauma admission, lower severity illness,
male sex, mechanical ventilation, high diastolic blood pressure,
vasopressor use, high diuretic volumes, and a less positive fluidciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
ue Country de ClinicalKey.es por Elsevier en junio 05, 2020.
ción. Copyright ©2020. Elsevier Inc. Todos los derechos reservados.
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clear influence on the pharmacokinetic profile of antimicrobial
drugs that are renally cleared, and research on the need to stage
ARC and establish specific dosing guidelines is warranted. Several
studies have shown a relationship between ARC and sub-
therapeutic levels of time-dependent antibiotics with renal
elimination, such as vancomycin and beta-lactams (Minkute
et al., 2013; 2012; Carlier et al., 2013), although there is less
information available for other drugs.
Linezolid, the first commercialized oxazolidinone antibiotic,
has activity against a wide variety of gram-positive microorgan-
isms, including methicillin-resistant Staphylococcus aureus (Cunha,
2006; Weigelt et al., 2005). The authorized dose of linezolid is
600 mg every 12 h, regardless of the patient’s hepatic or renal
function.
Linezolid is moderately bound to plasma proteins (31%), and the
volume of distribution is about 40–50 l, which is approximately the
total body water. Linezolid is metabolized by oxidation to two
inactive metabolites, and approximately 65% of its elimination is
through non-renal clearance (Bouza and Muñoz, 2001; Dryden,
2011). Renal clearance accounts for 30–35% of the total clearance,
and there is controversy regarding the correlation between
creatinine clearance and linezolid clearance. Some authors have
concluded that there is not a strong relationship, whereas others
have suggested that renal function is a relevant factor affecting the
pharmacokinetics of linezolid in critically ill patients, and thus the
probability of attaining the pharmacokinetic/pharmacodynamic
(PK/PD) target (Barrasa et al., 2019). It is important to bear in mind
that the pharmacokinetic profile of linezolid shows great
variability in critically ill patients (Meagher et al., 2003; Boselli
et al., 2005; Buerger et al., 2006; Adembri et al., 2008; Viaggi et al.,Table 1
Characteristics of patients stratified by level of renal function based on the creatinine 
ID Infection Sex AP II Age
(years)
Weight
(kg)
BMI
(kg/m2)
Cr
(mg/dl)
CrCL
(ml/m
Group I
1 Intra-abdominal M 30 77 85 27.8 0.9 43 
2 Respiratory M 12 76 65 23.4 1.5 44 
3 Respiratory F 13 70 78 25.4 0.7 53 
4 Others M 12 74 72 25.6 1.4 11 
5 Intra-abdominal M 16 85 75 23.1 1.0 39 
6 CNS F 13 79 80 26.6 1.0 51 
7 Respiratory M 36 77 65 23.9 2.1 28 
Mean 18.9 76.9 74.3 25.1 1.2 38.4 
SD 9.9 4.6 7.5 1.7 0.5 14.6 
Group II
8 Respiratory M 24 63 70 24.8 1.0 72.6 
9 CNS F 11 37 60 23.4 0.7 86.0 
10 Respiratory M 18 83 80 24.7 1.1 71.6 
11 CNS F 26 22 60 22.0 0.5 60.2 
12 Intra-abdominal F 21 47 60 20.8 0.8 101.0 
13 CNS M 12 81 85 26.8 0.8 99.2 
Mean 18.7 55.5 69.2 23.8 0.8 81.8 
SD 6.2 24.5 11.1 2.2 0.2 16.4 
Group III
14 CNS M NA 54 65 23.9 0.6 131.0 
15 CNS M 16 43 70 24.2 0.7 179.5 
16 Soft tissue M 14 49 95 29.3 0.8 167.0 
17 Respiratory M 15 65 90 26.3 0.4 135.4 
Mean 15.0 52.8 80.0 25.9 0.6 153.2 
SD 1.0 9.3 14.7 2.5 0.2 23.7 
p-Value NS NS NS NS 0.031* 0.001
Alb, albumin; AP II, Apache II score; BMI, body mass index; BR, bilirubin; CNS, central
glutamic oxaloacetic transaminase; GPT, serum glutamic pyruvic transaminase; Hb, he
prothrombin ratio, SD, standard deviation.
* Differences between groups I and III.
** Differences among all three groups.
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Thus, based on the reasons mentioned above, the aim of this
study was to assess the influence of renal function, especially the
presence of ARC, on the pharmacokinetics of linezolid after the
administration of the authorized standard dose (600 mg every
12 h) to critically ill patients. The influence of different dosage
strategies, such as continuous infusion, on the probability of
therapeutic success from a PK/PD point of view was also evaluated.
Materials and methods
Study design
A prospective open-label study was conducted on patients
admitted to the intensive care units (ICUs) of two Spanish
university hospitals: University Hospital Araba (Vitoria-Gasteiz)
and Doce de Octubre Hospital (Madrid). The protocol was approved
by the Basque Clinical Research Ethics Committee (LINE_IC_2015)
and the Spanish Agency of Medicinal Products and Medical Devices
(EudraCT No. 2015-002987-17). All patients or their legal
representatives were informed about this study and written
informed consent was obtained.
Patients, linezolid administration, and sample collection
Patients were eligible for inclusion if (1) they were admitted to
the ICU; (2) they suffered from an infection probably caused by a
Gram-positive microorganism and were therefore treated with
linezolid; (3) they gave informed consent; and (4) it was possible to
obtain plasma samples. The exclusion criteria were (1) age <18clearance rate.
in/ 1.73 m2)
Glucose
(mg/dl)
Hb
(g/dl)
Alb
(g/dl)
TP
(g/dl)
BR
(mg/dl)
GOT
(U/l)
GPT
(U/l)
PR
%
117 7.0 2.8 5.1 0.4 16 6 95
150 9.2 2.1 4.9 0.2 16 21 83
170 13.2 3.0 7.4 1.3 31 18 83
144 12.2 2.1 4.8 0.7 34 36 103
165 9.7 1.9 4.6 0.3 34 49 87
144 8.6 3.2 6.6 0.9 19 17 106
187 7.7 3.8 6.2 1.0 18 24 113
153.9 9.7 2.7 5.8 0.7 24.0 24.4 95.7
22.5 2.3 0.7 1.1 0.4 8.5 14.1 12.0
100 9.9 2.6 6.5 1.3 230 165 68
73 12.7 2.9 6.9 0.2 38 6 105
161 9.8 2.8 6.1 0.4 54 53 81
126 9.4 2.9 6.5 0.4 18 15 105
156 12.6 2.5 4.2 1.0 330 340 76
147 12.5 2.8 6.9 0.9 35 25 87
127.2 11.2 2.8 6.2 0.7 117.5 100.7 87.0
34.8 1.6 0.2 1.0 0.4 130.3 130.9 15.3
75 11.8 2.9 5.3 0.6 23 59 NA
113 15.5 4.0 6.8 1.0 16 15 110
106 8.1 2.5 5.5 0.8 102 112 70
162 13.0 2.5 4.8 0.6 48 52 99
114.0 12.1 3.0 5.6 0.8 47.3 59.5 93.0
36.0 3.1 0.7 0.9 0.2 39.0 40.0 20.7
** NS NS NS NS NS NS NS NS
 nervous system; Cr, creatinine; CrCL, creatinine clearance; F, female; GOT, serum
moglobin; M, male; NA, not available; NS, non-significant; TP, total proteins; PR,
que Country de ClinicalKey.es por Elsevier en junio 05, 2020.
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Figure 1. Linezolid plasma concentration versus time in patients grouped by renal
function. Filled circles: group I (CrCL <60 ml/min/1.73 m2); open diamonds: group
II (CrCL 60 and <130 ml/min/1.73 m2); grey triangles: group III (CrCL 130 ml/
min/1.73 m2).
H. Barrasa et al. / International Journal of Infectious Diseases 93 (2020) 329–338 331years; (2) pregnancy; (3) hypersensitivity to linezolid or any of the
excipients; and (4) being on any medicinal product that inhibits
monoamine oxidase A or B. Demographic, clinical, and biochemical
data at the time of inclusion in the study were obtained for all
patients.
The study was divided into two parts. In the first part, 17
patients recruited during a 3-year period (2013–2015) received
the standard dose of 600 mg administered every 12 h by
intravenous infusion over 30 min. Blood samples were collected
pre-dose, at the end of infusion, and at 1, 2, 3, 6, 8–10, and 12 h
under steady-state conditions over one dosing interval. Time
points were selected to adequately characterize the peaks and
troughs and the elimination phase. In most patients, blood
sample collection was performed within the first week of therapy.
Patients were grouped by renal function: group I included
patients with renal dysfunction, defined as CrCL <60 ml/min/
1.73 m2; group II patients had CrCL 60 and <130 ml/min/
1.73 m2; group III patients had ARC (CrCL 130 ml/min/1.73 m2).
In the second part, linezolid was administered as a continuous
infusion (infusion rate 50 mg/h) to 26 patients recruited from 2015
to 2017. The inclusion and exclusion criteria were the same as those
for the first part of the study, but, in addition, the presence of a CrCL
value <40 ml/min/1.73 m2 was added as an exclusion criterion to
avoid the potential accumulation of linezolid. These patients were
grouped into group IV (no ARC, CrCL >40 and <130 ml/min/
1.73 m2) if they were found not to have ARC on any day of the study
and into group V (ARC, CrCL 130 ml/min/1.73 m2) if ARC was
detected on at least 1 day of the study. One blood sample per
patient per day was obtained for 4 consecutive days.
Collected plasma samples were centrifuged and the plasma was
stored at 80 C until analysis. For all patients, CrCL was measured
using urine collected over a period of 10 h the night before each day
of the study, because the use of equations based on plasma
creatinine would not accurately show the patients’ renal function
(Barrasa et al., 2019; Baptista et al., 2011).
Linezolid quantification
Linezolid plasma concentrations were quantified using a
previously validated high performance liquid chromatography
(HPLC) assay with ultraviolet detection (at a wavelength of
254 nm), following the US Food and Drug Administration (FDA)
(FDA, 2018) and European Medicines Agency (EMA) (EMA, 2009)
guidelines for parameters such as specificity, linearity and range,
accuracy, precision, and stability. Separation was performed on a
Symmetry C8 column (4.6 mm  150 mm  5 mm). The mobile
phase contained ammonium phosphate (0.5%) and acetonitrile
(66:34, volume:volume) and was delivered at 1 ml/min. In brief,
sample preparation consisted of protein precipitation with acetoni-
trile, where propyl-4-hydroxybenzoate (internal standard) was
previously diluted. After centrifugation (10 min at 12 000 rpm),
the supernatants were injected into the HPLC system.
The assay was linearover the concentration range from 0.5 mg/ml
to 50 mg/ml. Specificity was assessed using six blank standards and
lower limit of quantification (LLOQ) level samples. The chromato-
grams were checked for any interference, and no interfering peaks
were detected with the assay. Intra-batch and inter-batch accuracy
and precision were evaluated at four different concentration levels
(LLOQ and low, middle, and high qualitycontrol) in six replicates. The
intra-day and inter-day coefficients of variation (CV) and bias were
never above 15%. Moreover, stock solution stability, long-term
storage stability, short-term temperature stability, freeze–thaw
stability of the analyte in the matrix from freezer storage conditions
to room temperature, and auto-sampler rack stability were
confirmed. Linezolid substance for standards and quality controls
was kindly provided by Pfizer Inc.Descargado para Anonymous User (n/a) en University of the Basque
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For the first part of the study, one- and two-compartment open
models with first-order elimination were explored to fit plasma
concentration–time data using Phoenix WinNonlin (version 6.4,
Pharsight Corporation). Objective function values, parameter
estimation precision, and goodness-of-fit plots were used as
model selection criteria.
For patients in whom linezolid was administered as a
continuous infusion, the total clearance (CL) was calculated for
each day as follows: CL = K0/C, where K0 is the infusion rate
constant and C the concentration measured each day. In addition,
the area under the plasma concentration–time curve at steady
state over 24 h (AUC24) was calculated for each day, using the
following equation: AUC24 = D/CL, where D is the daily dose
(1200 mg).
Pharmacokinetic/pharmacodynamic analysis (PK/PD)
The probability of target attainment (PTA), understood as the
probability of achieving a specific PK/PD index related to the
efficacy of an antibiotic treatment at a certain pathogen
susceptibility (minimum inhibitory concentration, MIC) (Mouton
et al., 2005), was calculated using Monte Carlo simulations
implemented in Oracle Crystal Ball Version 11.1.1.1.00. Linezolid
is an antibiotic with concentration- and time-dependent activity;
therefore, the time that plasma concentrations are above the MIC
(%T>MIC) and the AUC24/MIC ratio are the PK/PD parameters that
best predict clinical efficacy (Adembri et al., 2008; Craig, 2003;
Rayner et al., 2003). An AUC24/MIC > 80 and %T>MIC >85%
(Minichmayr et al., 2017; Barrasa et al., 2019) were selected as
the targets to calculate the probability of treatment success or PTA.
By using the PK parameters estimated in patients from groups I,
II, and III (mean values and variability, assuming lognormal
distribution), 1000 studies of 1000 subjects were simulated, to
calculate the PTA over a range of doubling MICs between 0.25 mg/l
and 8 mg/l. The 95% confidence intervals were calculated as the
range from the 2.5th to the 97.5th percentile of the set of estimated
values (Kümmel et al., 2018). Dosing regimens evaluated were
600 mg every 12 h and 600 mg every 8 h, administered as a 30-min
infusion.
From the values of the PK parameters calculated in patients
with ARC (groups III and V), Monte Carlo simulations were
conducted to estimate the PTA for linezolid continuous infusion at
rates of 50 mg/h and 75 mg/h. In this case, the PTA was defined as Country de ClinicalKey.es por Elsevier en junio 05, 2020.
n. Copyright ©2020. Elsevier Inc. Todos los derechos reservados.
Table 2
Pharmacokinetic parameters of linezolid in patients stratified by level of renal function and achievement of PK/PD target.
Pharmacokinetics Pharmacodynamics
ID Vd
(l)
Vd/kg
(l/kg)
t1/2
(h)
CL
(l/h)
AUC24
(mg h/l)
Cmax
(mg/l)
Cmin
(mg/l)
%T>MIC >85%
(MIC =2 mg/l)
AUC24/MIC > 80
(MIC =2 mg/l)
Group I
1 35.8 0.4 6.3 3.96 303.4 25.1 6.2 Yes Yes
2 54.7 0.8 6.2 6.11 196.2 19.3 4.5 Yes Yes
3 28.8 0.4 3.8 5.32 225.5 26.8 3.6 Yes Yes
4 28.8 0.4 2.1 9.64 124.5 22.7 1.5 No No
5 27.6 0.4 4.8 4.01 299.4 28.5 5.6 Yes Yes
6 33.6 0.4 4.0 5.86 204.7 25.9 3.2 Yes Yes
7 37.8 0.6 7.2 3.64 329.0 24.1 6.7 Yes Yes
Mean 35.3 0.5 4.9 5.5 240.4 24.6 4.5
SD 9.4 0.2 1.8 2.1 73.2 8.7 1.8
Group II
8 75.8 1.1 6.0 8.71 137.8 10.9 2.8 Yes No
9 38.3 0.6 4.1 6.48 185.1 16.1 2.5 Yes Yes
10 39.3 0.5 5.6 4.87 246.5 22.4 4.9 Yes Yes
11 37.1 0.6 4.6 5.65 212.4 21.3 2.2 Yes Yes
12 38.6 0.6 4.0 6.72 178.6 19.2 3.3 Yes Yes
13 36.8 0.4 4.9 5.21 230.0 20.9 3.9 Yes Yes
Mean 44.3 0.6 4.9 6.3 198.4 18.5 3.3
SD 15.5 0.2 0.8 1.4 39.4 4.3 1.0
Group III
14 61.2 0.9 1.1 38.8 31.0 9.2 0.1 No No
15 33.4 0.5 0.7 32.3 37.2 15.2 0.4 No No
16 54.8 0.6 1.1 33.8 35.5 10.1 0.4 No No
17 44.5 0.5 1.5 20.5 58.7 12.9 0.2 No No
Mean 48.5 0.6 1.1 31.3 40.6 11.9 0.3
SD 12.2 0.2 0.3 7.8 12.3 2.7 0.1
p-Value NS NS <0.001* <0.001* <0.001* 0.006** <0.001*
AUC24, area under the plasma concentration–time curve in a period of 24 h; CL, plasma clearance; Cmax, maximum plasma linezolid concentration; Cmin, minimum plasma
linezolid concentration; MIC, minimum inhibitory concentration; NS, non-significant; PK/PD, pharmacokinetics/pharmacodynamics; SD, standard deviation; %T>MIC, time
that plasma concentrations are above the MIC; t1/2, half-life; Vd, volume of distribution.
* Differences between groups I and II versus group III.
** Differences among all three groups.
Table 3
Probability of target attainment (PTA) for linezolid in simulated patients receiving
600 mg q12 h or 600 mg q8h. Numbers in parenthesis indicate the 2.5th and 97.5th
percentiles.
AUC24/MIC >80 %T>MIC >85%
MIC (mg/l) 600 mg q12h 600 mg q8h MIC (mg/l) 600 mg q12h
Group I
0.25 100 100 100 100
0.50 100 100 99 (98–100) 100
1 100 100 95 (94–97) 100
2 85 (82–86) 98 (98–99) 86 (84–88) 98 (97–99)
4 21 (17–23) 60 (57–63) 58 (55–61) 90 (88–92)
8 1 (0–2) 5 (4–7) 22 (19–26) 60 (57–63)
Group II
0.25 100 100 100 100
0.50 100 100 99 (99–100) 100
1 100 100 98 (84–89) 100
2 85 (83–87) 100 (99–100) 86 (84–89) 99 (99–100)
4 1 (1–2) 34 (31–37) 49 (46–51) 93 (92–95)
8 0 0 4 (3–5) 47 (44–50)
Group III
0.25 100 100 5 (3–6) 41 (38–44)
0.50 45 (43–48) 95 (93–96) 1 (1–2) 19 (17–21)
1 0 11 (9–13) 0 4 (3–6)
2 0 0 0 0
4 0 0 0 0
8 0 0 0 0
AUC24, area under the plasma concentration–time curve in a period of 24 h; MIC,
minimum inhibitory concentration; q12 h, every 12 h; q8h, every 8 h; %T>MIC, time
that plasma concentrations are above the MIC.
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steady state above the MIC value (C  MIC).
The dosing regimens were considered optimal if the PTA was
90%, whereas a PTA between 80% and 90% was considered to
indicate a moderate probability of success (Asuphon et al., 2016;
Drusano et al., 2004; Bradley et al., 2003).
Statistical analysis
The statistical analysis was performed using IBM SPSS Statistics
for Windows, version 22. The normality of the data distribution
was assessed with the Shapiro–Wilk test and the homogeneity of
variance with the Levene test, while the t-test, Mann–Whitney
U-test, analysis of variance (ANOVA), or Kruskal–Wallis test was
used to compare the physiological and pharmacokinetic param-
eters of linezolid between patients in the different groups, as
appropriate. Spearman correlation coefficients were calculated to
determine the correlation between estimated AUC24 and observed
trough concentrations (Cmin) and between linezolid clearance and
CrCL. Statistical significance was set at p < 0.05.
Results
Seventeen critically ill patients with different levels of renal
function were included in the first part of the study: seven in group
I (CrCL <60 ml/min/1.73 m2), six in group II (CrCL 60 and <130 ml/
min/1.73 m2), and four in group III (CrCL 130 ml/min/1.73 m2).
Table 1 summarizes demographic, anthropometric, and illnessDescargado para Anonymous User (n/a) en University of the Basque Country de ClinicalKey.es por Elsevier en junio 05, 2020.
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Figure 2. Estimated probability of target attainment (PTA) values with the four dose regimens in each group of simulated patients.
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respiratory in six cases, neurological in six, abdominal in three,
and soft tissues in one, with ‘other sources’ being cited in one other
case. Differences between groups were only significant for serum
creatinine and CrCL. No adverse effects attributable to linezolid
treatment were reported.
Overall, 136 plasma samples were analyzed. Figure 1 displays
the plasma concentrations of linezolid over time in the three
groups. In groups I, II, and III, the linezolid concentration ranged
from 19.3 mg/l to 28.5 mg/l, from 10.9 mg/l to 22.4 mg/l, and from
9.2 mg/l to 15.2 mg/l, respectively, at the end of the infusion and
from 1.5 mg/l to 6.7 mg/l, from 2.2 mg/l to 4.9 mg/l, and from
0.1 mg/l to 0.4 mg/l, respectively, at the end of the dosing interval
(12 h after infusion). Plasma concentrations of linezolid were
markedly lower in the samples from group III than in those from
the other two groups, while differences between groups I and II
were less marked.Descargado para Anonymous User (n/a) en University of the Basque
Para uso personal exclusivamente. No se permiten otros usos sin autorizacióA one-compartment open model was selected to explain and
compare the pharmacokinetic parameters of linezolid. Table 2 lists
the calculated values in all of the patients. Significant differences
were detected between group III and the other two groups in
elimination half-life (t1/2), CL, AUC24, and Cmin. In groups I and II,
t1/2 was significantly higher than in group III (4.9 h vs 1.1 h) and CL
was nearly 5-fold lower; consequently, AUC24, maximum plasma
linezolid concentration (Cmax), and Cmin were significantly higher
(p < 0.006). Significant differences were only observed for Cmax
between groups I and II, with higher values in group I (24.6 mg/l vs
18.5 mg/l). For a MIC of 2 mg/l, the AUC24/MIC was >80 and %T>MIC
was >85% in more than 80% of the patients in groups I and II.
However, no patient with ARC attained the values related to
efficacy for either of the two PK/PD targets (Table 2).
Table 3 and Figure 2 feature the PTA values calculated by Monte
Carlo simulation for the targets AUC24/MIC > 80 and %T>MIC >85%.
The standard dose (600 mg every 12 h) provided PTA values higher Country de ClinicalKey.es por Elsevier en junio 05, 2020.
n. Copyright ©2020. Elsevier Inc. Todos los derechos reservados.
Table 4
Characteristics of patients stratified by whether they had augmented renal clearance (ARC).
ID Infection Sex AP
II
Age
(y)
Weight
(kg)
BMI
(kg/m2)
Glucose
(mg/dl)
CrCLa
(ml/min/ 1.73 m2)
Hb
(g/dl)
Alb
(g/dl)
TP
(g/dl)
BR
(mg/dl)
GOT
(U/l)
GPT
(U/l)
PR
%
Group IV (No ARC)
1 CNS F 23 84 70 25.7 217 65–85 11.5 3.0 5.4 0.6 18 20 83
2 CNS M 11 72 80 29.4 115 77–128 10.1 3.0 5.4 0.8 16 18 69
3 Intra-abdominal F 19 42 51 NA 165 73–115 8.5 2.2 4.9 3.8 41 27 68
4 CNS M 9 65 70 25.7 94 69–70 10.9 2.7 NA 0.2 59 57 97
5 CNS M 18 46 90 27.8 173 85–129 11.4 3.1 NA 0.3 87 76 69
6 CNS M 12 51 85 27.8 144 106–126 9.7 3.5 7.4 0.6 27 40 80
7 Respiratory F 9 58 70 27.3 176 41–66 8.7 3.1 5.6 0.5 49 24 72
8 Respiratory F 10 76 75 27.5 159 74–83 9.4 3.9 6.6 0.4 33 35 101
9 CNS F 16 59 63 28.0 69 88–122 10.7 2.7 5.1 0.4 22 32 78
10 Respiratory M 16 22 NA NA 125 76–123 10.9 3.1 5.6 0.3 43 37 99
11 Respiratory M 23 71 72 27.8 112 84–87 11.4 2.2 5.2 1.1 41 25 74
12 CNS M 14 76 70 24.2 184 63–77 10.6 2.5 4.9 0.2 19 12 98
13 Respiratory M 18 68 70 22.9 122 66–127 7.9 2.7 6.1 1.1 36 49 81
Mean 15.2 60.8 72.2 26.7 142.7 10.1 2.9 5.7 0.8 37.8 34.8 82.2
SD 4.9 17.0 10.0 1.9 41.1 1.2 0.5 0.8 1.0 19.7 17.6 12.4
Group V (ARC)
14 Respiratory M 17 48 95 30.0 139 115–153 10.6 3.1 6.3 2.1 74 220 75
15 CNS F 6 68 80 29.4 133 45–155 8.4 2.6 5.5 0.5 16 21 79
16 CNS M 25 71 75 27.5 157 86–146 11.7 3.6 6.7 1.1 24 34 128
17 Others F 21 27 70 24.2 117 118–138 8.2 2.5 5.3 0.8 41 42 92
18 Respiratory M 16 24 115 35.5 114 160–240 11 2.7 5.4 0.5 70 61 86
19 Respiratory M 9 40 65 21.2 113 125–180 13.7 2.8 6.4 0.3 38 39 112
20 Respiratory M 35 78 75 24.5 111 125–160 11.6 3.0 5.6 0.3 60 89 82
21 Respiratory M 10 47 70 24.2 116 94–170 11.6 3.5 6.3 1.3 161 40 83
22 CNS M 12 62 82 31.2 169 130–245 14.9 3.5 7.5 0.5 28 15 69
23 Respiratory M 14 45 81 28.7 152 185–220 8.1 3.0 5.6 0.4 31 35 84
24 Respiratory M 8 48 101 30.5 120 278–345 8 2.5 4.7 0.2 76 77 84
25 Respiratory F 6 34 122 46.5 78 230–331 10.7 3.9 6.5 0.3 84 63 90
26 Others M 20 50 89 28.4 113 220–339 8.8 2.5 6.9 0.5 25 23 67
Mean 15.3 49.4 86.2 29.4 125.5 10.6 3.0 6.1 0.7 56.0 58.4 87.0
SD 8.4 16.6 17.6 6.4 24.0 2.2 0.5 0.8 0.5 39.0 53.3 16.7
p-Value NS NS 0.023 NS NS NS NS NS NS NS NS NS
Alb, albumin; AP II, Apache II score; BMI, body mass index; BR, bilirubin; CNS, central nervous system; CrCL, creatinine clearance; F, female; GOT, serum glutamic oxaloacetic
transaminase; GPT, serum glutamic pyruvic transaminase; Hb, hemoglobin; M, male; NA, not available; NS, non-significant; TP, total proteins; PR, prothrombin ratio, SD,
standard deviation.
a Minimum and maximum CrCL during the study.
Figure 3. Linezolid plasma concentration versus time in patients grouped by the
presence (grey diamonds, group V) or not (white triangles, group IV) of ARC.
334 H. Barrasa et al. / International Journal of Infectious Diseases 93 (2020) 329–338than 80% for microorganisms up to a MIC of 2 mg/l in patients
without ARC (groups I and II). In contrast, in patients with ARC
(CrCL 130 ml/min/1.73 m2, group III), neither 600 mg every 12 h
nor 600 mg every 8 h provided PTA values 80% for the MIC of
2 mg/l, these being close to zero.
The second part of the study included 26 critically ill patients
with CrCL 40 ml/min/1.73 m2 who received linezolid as a
continuous infusion at a rate of 50 mg/h. Table 4 summarizes
the demographic and clinical data for these patients. Figure 3
shows the plasma concentrations over time in these patients.
Overall, 94 plasma samples were analyzed. The linezolid concen-
tration ranged from 1.3 mg/l to 15.5 mg/l in group IV and from
1.0 mg/l to 7.4 mg/l in group V. Table 5 presents the daily CrCL and
the pharmacokinetic parameters for each subject. The mean daily
CrCL ranged from 81.2 ml/min/1.73 m2 to 93.5 ml/min/1.73 m2 in
group IV (no ARC) and from 167.9 ml/min/1.73 m2 to 197.4 ml/min/
1.73 m2 in group V (ARC). Linezolid CL was significantly higher
(p < 0.05) in the patients with ARC, with this leading to
significantly lower values of C (p < 0.05) and AUC24 (p < 0.05).
Linezolid concentrations were maintained above 2 mg/l in 94% of
samples from patients without ARC (group IV) and in 70% of
samples from patients with ARC (group V). No adverse effects
attributable to linezolid were observed.
Figure 4 shows the PTA values calculated by Monte Carlo
simulation for virtual patients with ARC receiving linezolid as a
continuous infusion at two different rates: 50 mg/h and 75 mg/h. ItDescargado para Anonymous User (n/a) en University of the Bas
Para uso personal exclusivamente. No se permiten otros usos sin autorizwas observed that the probability of attaining the PK/PD target was
notably higher than with the intermittent infusions. With
continuous infusion, for a MIC of 2 mg/l, the PTA was 68% for
50 mg/h and 93% for 75 mg/h.
Figure 5 shows the correlation between CrCL and linezolid CL,
obtained with all values from the five groups of patients;
Spearman’s correlation coefficient was 0.77 (p < 0.001).que Country de ClinicalKey.es por Elsevier en junio 05, 2020.
ación. Copyright ©2020. Elsevier Inc. Todos los derechos reservados.
Table 5
Pharmacokinetic parameters of linezolid stratified by whether the patient had augmented renal clearance (ARC).
Day 1 Day 2 Day 3 Day 4
ID CrCL
(ml/min/1.73m2)
C
(mg/l)
CL
(l/h)
AUC24
(mg h/l)
CrCL
(ml/min/1.73m2)
C
(mg/l)
CL
(l/h)
AUC24
(mg h/l)
CrCL
(ml/min/1.73m2)
C
(mg/l)
CL
(l/h)
AUC24
(mg h/l)
CrCL
(ml/min/1.73m2)
C
(mg/l)
CL
(l/h)
AUC24
(mg h/l)
Group IV (No ARC)
1 85 9.3 5.4 222 72 8.6 5.8 207 65 9.1 5.5 218 65 9.1 5.5 218
2 77 5.5 9.0 133 128 3.2 15.8 76 105 4.2 12.1 100 105 4.2 12.1 100
3 73 15.5 3.2 371 78 13.8 3.6 332 91 12.4 4.0 298 91 12.4 4.0 298
4 70 3.2 15.7 76 69 4.3 11.7 103 69 8 6.2 193 69 8 6.2 193
5 123 4.5 11.2 107 129 6.7 7.5 161 85 6.7 7.5 161 85 6.7 7.5 161
6 106 1.3 37.3 32 126 2.4 21.3 56 111 1.9 26.4 45 111 1.9 26.4 45
7 53 13.2 3.8 316 66 11.9 4.2 285 41 14.1 3.5 339 41 14.1 3.5 339
8 83 6.5 7.7 156 74 NA NA NA NA NA NA NA NA NA NA NA
9 97 14.1 3.5 339 88 9.0 5.6 216 112 9.5 5.3 227 112 9.5 5.3 227
10 123 5.7 8.8 136 115 5.9 8.4 142 76 6.2 8.1 148 76 6.2 8.1 148
11 84 9.8 5.1 236 87 7.5 6.7 179 NA 7.1 7.1 170 NA 7.1 7.1 170
12 70 8.0 6.2 193 77 11 4.5 265 60 13.6 3.7 326 60 13.6 3.7 326
13 127 7.3 6.8 175 86 9.1 5.5 218 78 9.2 5.4 221 78 9.2 5.4 221
Mean 90.1 8.0 9.5 191.7 91.9 7.8 8.4 186.7 81.2 8.5 7.9 203.8 93.5 7.4 9.2 177.5
SD 23.4 4.3 9.0 102.6 23.8 3.5 5.3 84.3 22.4 3.7 6.3 88.1 25.1 3.6 6.7 86.9
Group V (ARC)
14 153 1.9 26.2 46 115 1.8 27.3 44 127 2.1 24.1 50 141 2.0 25.3 47
15 45 2.6 18.9 63 84 3.1 16.4 73 155 2.8 17.7 68 107 4.5 11.2 107
16 92 3.0 16.5 73 146 4.0 12.7 95 86 6.0 8.4 144 87 6.0 8.4 143
17 120 3.1 15.9 75 138 3.5 14.2 84 118 2.4 21.3 56 128 2.2 22.9 52
18 182 1.6 31.2 38 208 2.1 23.8 50 240 2.5 19.9 60 160 2.7 18.8 64
19 125 3.7 13.5 89 130 1.9 25.7 47 153 2.1 24.3 49 180 2.5 19.9 60
20 147 2.6 19.6 61 153 2.4 20.6 58 125 3.7 13.5 89 160 4.6 10.8 111
21 170 6.1 8.2 146 94 7.4 6.8 177 NA NA NA NA NA NA NA NA
22 170 1.7 29.2 41 230 2.1 23.5 51 130 2.0 25.6 47 245 1.8 27.2 44
23 185 2.9 17.4 69 210 2.6 19.6 61 220 2.5 20 60 NA 1.2 42.7 28
24 340 1.6 32.1 37 280 1.4 36.7 33 345 1.6 30.6 39 278 1.5 32.7 37
25 234 1.0 48.4 25 264 1.6 30.7 39 331 1.6 30.9 39 230 1.4 36.5 33
26 220 2.3 22.0 55 238 3.4 14.7 82 339 3.4 14.8 81 277 3.4 14.9 81
Mean 167.9 2.6 23.0 62.9 176.2 2.9 21.0 68.8 197.4 2.7 20.9 65.2 181.2 2.8 22.6 67.3
SD 72.4 1.3 10.4 30.9 65.4 1.6 8.1 37.6 95.0 1.2 6.7 29.2 66.9 1.5 10.8 36.0
AUC24, area under the plasma concentration–time curve in a period of 24 h; CL, linezolid clearance; CrCL, creatinine clearance; C, linezolid concentration each day of the study (days 1–4); NA, not available; SD, standard deviation.
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Figure 5. Correlation between CrCL and linezolid clearance.
Figure 4. Estimated probability of target attainment (PTA) values with the
continuous infusion of linezolid at rates of 50 mg/h and 75 mg/h.
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This study is novel in showing that the presence of ARC in
critically ill patients significantly affects the pharmacokinetics of
linezolid, as well as in evaluating the effect of ARC on the adequacy
of the dosing regimen. ARC is a clinical stage that can lead to faster
elimination of drugs, resulting in sub-therapeutic concentrations
and poorer clinical outcomes when standard dosage guidelines are
followed (Bilbao-Meseguer et al., 2018). This is particularly
important for antibacterial agents that are eliminated by the
kidney and whose activity is time-dependent (Carlier et al., 2013;
Udy et al., 2010; Udy et al., 2012).
The total number of patients with ARC included in this study
was 17, representing 40% of all recruited patients; this is similar to
other series (Udy et al., 2014). We defined ARC as the clinical
situation in which CrCL was 130 ml/min/1.73 m2 on at least 1 day
of the study, as proposed by most authors (Bilbao-Meseguer et al.,
2018; Udy et al., 2014). In other studies, patients have been
considered to have ARC if more than 50% of the CrCL measure-
ments during admission were 130 ml/min/1.73 m2. Other works,
however, have shown that between 55.4% and 74% of patients who
have CrCL 130 ml/min/1.73 m2 in one measurement have values
higher than this level in more than 50% of measurements (Baptista
et al., 2011; Udy et al., 2014). In another study, it was reported that a
high percentage of patients with CrCL 130 ml/min/1.73 m2
measured once, had ARC throughout their ICU stay (De Waele
et al., 2015).Descargado para Anonymous User (n/a) en University of the Bas
Para uso personal exclusivamente. No se permiten otros usos sin autorizWhen comparing patient characteristics among groups, it was
observed that, although patients with ARC seemed to be younger
and had a lower severity illness score, differences among the
groups were not statistically significant. Moreover, no patients
received concomitant medication that could modify linezolid
pharmacokinetics. Therefore, the observed differences in drug
pharmacokinetics and in PK/PD results cannot be attributed to
these factors.
The standard dose of linezolid is 600 mg every 12 h adminis-
tered as an intermittent infusion over the course of 30 min.
Bearing in mind that only 30–35% of linezolid is excreted in urine
(Stalker and Jungbluth, 2003), no dosage adjustments are
recommended in patients with renal dysfunction. However, at
the other end of the renal function spectrum, i.e. patients with
ARC, dose recommendations have not been established, and
whether or not higher doses are required has not been adequately
studied.
This study confirmed that if the patient does not have ARC,
differences in CrCL do not lead to changes in linezolid CL, and
therefore dose adjustment is not necessary; this supports the
recommendations of the clinical practice guidelines. Moreover,
we also found that the standard dose (600 mg every 12 h as a
30-min infusion) provides a high probability of treatment success
in patients with infections due to microorganisms with a
MIC  2 mg/l, which is the European Committee on Antimicrobial
Susceptibility Testing (EUCAST) PK/PD (non-species related)
breakpoint for linezolid and the MIC90 of most Staphylococcus
species in Europe (EUCAST, 2018).
In contrast, in the presence of ARC, there is a significant increase
in linezolid clearance and a high risk of underexposure. Actually,
the PK/PD targets (AUC24/MIC > 80 and %T>MIC>85%) for the MIC of
2 mg/l were not reached in any of the patients with ARC. Moreover,
the PK/PD analysis and Monte Carlo simulation revealed that
600 mg every 8 h, also given as a 30-min infusion, did not
substantially increase the probability of treatment success, being
very low for MICs higher than 0.5 mg/l; this makes the intermittent
infusion of linezolid at the doses evaluated inappropriate for this
group of patients.
We found only one relevant case in the literature, which
reported the pharmacokinetics of linezolid in a woman with ARC
receiving 600 mg every 12 h (Cojutti et al., 2018). As in our study,
linezolid CL was higher than that observed in healthy volunteers;
moreover, therapeutic drug monitoring revealed suboptimal
exposure, with Cmin of 0.3 mg/l, similar to that obtained in our
patients.
Previous studies have suggested that continuous infusion of
linezolid may be an alternative to ensure antibiotic exposure in
critically ill patients (Adembri et al., 2008; Dong et al., 2011;
Richards and Brink, 2014). Thus, in the second part of the study, we
sought to determine whether the administration of linezolid as a
continuous instead of an intermittent infusion to patients with
high CL could improve their exposure to the antibiotic and
therefore increase the probability of treatment success. With this
purpose in mind, we administered linezolid to patients at an
infusion rate of 50 mg/h (same daily dose as the standard dose) and
investigated whether this dosing regimen would be sufficient to
provide plasma concentrations (C) 2 mg/l (PK/PD target). It was
observed that this target was reached in 94% of the patients with
CrCL <130 ml/min/1.73 m2, and what is more relevant, in 70% of the
patients with ARC.
Monte Carlo simulations confirmed that the administration of
linezolid to patients with ARC as a continuous infusion of 50 mg/h
notably increases the probability of attaining the PK/PD target,
being close to 100% for a MIC of 1 mg/l and almost 70% for a MIC of
2 mg/l, which agrees with the results obtained experimentally.
Additionally, we simulated the administration of linezolid as aque Country de ClinicalKey.es por Elsevier en junio 05, 2020.
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H. Barrasa et al. / International Journal of Infectious Diseases 93 (2020) 329–338 337continuous infusion of 75 mg/l and found that with this dosing
regimen, the probability of treatment success in patients with ARC
and infections due to microorganisms with a MIC of 2 mg/l
increases to 93%. These results confirm that linezolid administered
as a continuous infusion may be an adequate alternative for
patients with ARC, although we have to bear in mind that the
unique dose regimen included in the summary of product
characteristics is 600 mg twice daily.
As mentioned previously, the relationship between CrCL and
linezolid CL is controversial. In fact, dose adjustment is not
required in patients with renal failure. From the CrCL and linezolid
CL values measured in our patients, a significant (p < 0.001)
correlation was established, with Pearson coefficient of 0.77
(Figure 4). However, it can be observed that for CrCL <100 ml/min/
1.73 m2, the correlation is very weak, which confirms that dose
adjustment is not necessary in patients with renal insufficiency. In
contrast, if the patient presents ARC, the subsequent increase in
linezolid CL justifies the need to modify the dosing strategy to
ensure adequate antibiotic exposure.
Regarding distribution, the mean Vd approximated the total
body water (35–49 l), and was similar to values obtained in
other studies on critically ill patients (Ide et al., 2018) and on
healthy volunteers (Slatter et al., 2001). Although the Vd of
many drugs is known to be modified in critically ill patients, this
occurs principally with hydrophilic molecules. The moderate
lipophilic nature of linezolid may explain the lack of differences
in this parameter among critically ill patients and healthy
volunteers.
The great variability in linezolid pharmacokinetics, described
previously by other authors (Dong et al., 2011; Zoller et al., 2014)
and confirmed in the present study, justifies the use of therapeutic
drug monitoring as a helpful tool for optimizing linezolid therapy
(Richards and Brink, 2014), especially in patients with ARC (Cojutti
et al., 2018). In our opinion, Cmin and C (in the case of
administration as a continuous infusion) of 2 mg/l are good
targets, considering that this is the EUCAST non-species related
breakpoint for linezolid.
This study has some limitations. First of all, linezolid was
administered as an empirical treatment. Microbiological analysis
found no microorganisms susceptible to linezolid in most of the
samples obtained, and therefore direct pharmacodynamic corre-
lation was not possible. Second, the concentration of linezolid in
urine was not measured, which may have provided more
information on the contribution of renal clearance to total
clearance of linezolid.
In conclusion, this study shows that ARC significantly increases
linezolid CL and leads to a high risk of suboptimal exposure when
the standard dose is used. Continuous infusion may be a useful
strategy to increase the probability of treatment success, becoming
one of the few options for patients with ARC. To ensure drug
concentrations above 2 mg/ml in these patients, a higher infusion
rate (75 mg/h) should be considered.
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